Mirum Pharmaceuticals to Host Investor Call on Phase 3 Study Results

Mirum Pharmaceuticals announced an investor call scheduled for October 12, 2026, at 8:30 a.m. The upcoming disclosure contrasts with the company’s recent regulatory achievements in its rare disease portfolio, highlighting an aggressive pipeline expansion running alongside established commercial products.

Innovative Therapies for Rare Liver Diseases

The EXPAND study targets ultra-rare cholestatic liver diseases, including biliary atresia, reflecting Mirum’s deep expertise in developing innovative therapies for specific rare conditions. Mirum’s commercial portfolio includes LIVMARLI, ATEBRIOZ, CHOLBAM, and CTEXLI, which address rare liver and genetic diseases. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter inhibitor used for treating cholestatic pruritus in patients with Alagille syndrome in the United States and various other countries, as well as for progressive familial intrahepatic cholestasis in the U.S., Canada, and Japan. Cholbam is used for bile acid synthesis disorders due to single enzyme deficiencies and as an adjunctive treatment for peroxisomal disorders.

For the AZURE-1 trial, the combined endpoint of virologic response and ALT normalization was met by 56 percent of patients in the 300 mg weekly group and 45 percent of those in the 900 mg every four weeks arm, surpassing the 0 percent seen in the delayed treatment cohort with a p-value of less than 0.0001. Forty-eight-week data from the Phase 2b portion showed virologic response rates increased from 45 percent and 35 percent at 24 weeks to 55 percent for both dosing regimens. Treatment-related adverse events were 23.7 percent for the 300 mg group and 33.8 percent for the 900 mg group, with no new safety signals identified.

Regulatory Approvals and Commercial Milestones

The U.S. Food and Drug Administration approved Atebrioz (zilurgisertib) for reducing total new heterotopic ossification volume in patients aged 12 and older with fibrodysplasia ossificans progressiva, marking a major commercial addition. In the PROGRESS study, patients receiving zilurgisertib showed a mean reduction of 3.2 cubic centimeters in new heterotopic ossification volume over 24 weeks, compared to a 24.6 cubic centimeter increase in the placebo group. In April, Mirum acquired worldwide global rights for zilurgisertib from Incyte through an initial $16 million payment, alongside contingent milestones related to regulation and sales. The treatment is expected to be available in the U.S. in October, supported by the Mirum Access Plus program to provide insurance coverage, financial assistance, and personalized support.

Wall Street analysts forecast Mirum stock price to rise from its current level of 81.350, driven by these pipeline advancements and regulatory clearances. Mirum plans to submit a Biologics License Application to the FDA for brelovitug in the first half of 2027, targeting a potential commercial launch in the fourth quarter of 2027. Meanwhile, the clinical pipeline continues to advance volixibat as an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis.

Whether the upcoming EXPAND study data for LIVMARLI in patients aged 6 months and older will support expanded labeling is uncertain at this point, when management hosts the webcast on October 12, 2026. Market observers are also tracking how quickly the newly approved Atebrioz will translate into commercial revenue following its October U.S. availability, and whether the planned 2027 Biologics License Application for brelovitug stays on schedule.